On the evening of the 5th, CanSino (688185.SH) announced that it had terminated the commercialization cooperation with Pfizer. The cooperation project is: ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Manhaixin (hereinafter referred to as: MCV4). This is causing concern among investors. On the one hand, the MCV4 involved in the announcement is a blockbuster product that CanSino Biology plans to launch in 2022. It is currently an exclusive domestic product and is expected to bring sales revenue of over 100 million yuan to the company. Dongxing Securities believes that if MCV4 achieves a neonatal penetration rate of 6%/10% from 2022 to 2023, the revenue contribution is expected to reach 810/1.35 billion yuan. On the other hand, the aforementioned announcement also involves Pfizer, the leading foreign pharmaceutical company, which is dubbed the “first pharmaceutical company in the universe” by the industry. In July 2020, CanSino signed a cooperation agreement with Pfizer. Pfizer has the right to exclusively promote its MCV4 in mainland China, and the cooperation period can be up to 10 years. Originally, the exclusive variety + blessing from Pfizer can be described as “a combination of two swords”. Until the end of 2021, CanSino also commented in the annual report.
[related_posts_by_tax taxonomies=”post_tag”]
The post CanSino officially launched the sales war: Termination of cooperation with “Universe First Pharmaceutical Factory” appeared first on Gamingsym.